Clinical trial support specialist Medidata has been selected by CTI Clinical Trial and Consulting, a contract research organization (CRO) on use of study technology. The CRO intends to use Medidata’s Remote Source Review, to monitor operations remotely and review documents across multiple sites across the globe, including COVID-19 projects.
With the pandemic causing significant interruptions in clinical studies, sites and sponsors are on the hunt for ways to permit their work to continue with minimal or no interruption. To that end, CTI opted to bring in Remote Source Review to help overcome travel restrictions, patients reluctant to visit sites, and other challenges with technology that supports remote review and other offsite processes.
According to Glen de Vries, co-founder and CEO of Medidata, the company is working to promote ways to develop and deploy technology enabling sites and sponsors to keep going.
“We’re pleased to be partnering with CTI on these important, promising trials for patients with rare and infectious diseases, and cancer. It’s more important than ever that we think and plan our way around the obstacles COVID-19 has put in the path of medical progress,” de Vries commented.
According to the company, Remote Source Review already is in service at more than 15,000 clinical trial sites. It reportedly proves especially useful when critical timelines, patient security and data integrity are of particular concern; the tool also helps users boost clinical research associate (CRA) productivity and expense levels by eliminating time and costs spent on travel.
Timothy Schroeder, CEO and founder of CTI, said remote solutions can be especially useful when clinical trial teams are looking for ways to ensure continuity.
“Standardizing our trials with Medidata technology and enhancing our remote monitoring capabilities are critically important during the pandemic,” he said. “Their scalable solutions will also take us beyond COVID-19. The future lies in minimizing disruptions to research, accelerating the move toward more virtual trial management, ensuring data collection and integrity, and managing source documents remotely, as needed.”
